Novo Nordisk India head eyes 2026 launch for obesity drug Wegovy, warns against copycats

Novo Nordisk plans to bring its weight-loss drug, Wegovy, to India in 2026. The company aims to secure regulatory approvals and ensure sufficient supply before entering the Indian market, where obesity rates are high. Counterfeit versions of Wegovy are already being sold online, but Novo Nordisk urges patients not to buy them due to safety concerns.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jD4NF9t
via IFTTT